Dynavax Technologies | Toll-like Receptor

Protection for an unpredictable world

We are developing cutting-edge vaccines by utilizing our innovative adjuvant technology and our expertise of Toll-like Receptor (TLR) biology to modulate the immune system.

TLR Biology

HEPLISAV-B®
[HEPATITIS B VACCINE (RECOMBINANT) ADJUVANTED]

Focusing on Developing Innovative Vaccines

Utilizing innovative adjuvant technology, Dynavax is leveraging Toll-like receptor (TLR) biology to stimulate the innate immune system to trigger a specific adaptive immune response to specific disease antigens for improved vaccines.

Learn more about our Product

Recent News

Dec 16, 2019

Dynavax Appoints Ryan Spencer as Chief Executive Officer and to Board of Directors

Dec 05, 2019

Dynavax Announces Partnership with Albertsons Companies’ Pharmacies to Offer HEPLISAV-B® Hepatitis B Vaccine to Patients Nationwide

View All News